Transforming Myasthenia Gravis Care
Ask the Expert: How to Use FcRn Blockers for Myasthenia Gravis EBAC ACCREDITED
Tuesday, 30 June 2026 | 18:00 - 18:30 CEST
Supported by an independent sponsorship from Johnson & Johnson.
overview
The final webinar of our 3-part series bridges the gap between foundational science and clinical action, focusing on the seamless integration of neonatal Fc receptor (FcRn) blockers into the modern treatment algorithm of myasthenia gravis (MG). This session equips clinicians with the decision-making tools necessary to move beyond standardized protocols toward truly personalized therapy. [para] Join the livestream to master the application of targeted therapy in real clinical practice.
faculty
agenda
18:00 CEST
Welcome and Introduction: An Evolving Management Approach
Bienvenido desde la llamada
0
0
0
0
18:03 CEST
Identifying Appropriate Patients and Preparing for FcRn Blocker Use
0
0
0
0
18:10 CEST
Practical Tips on Choosing and Using FcRn Blockers
0
0
0
0
18:25 CEST
Q&A, Summary, and EBAC Evaluation
0
0
0
0
target audience
This educational activity is intended for an audience of neurologists, ophthalmologists, primary care physicians, and other healthcare providers caring for patients with MG in Europe, the Middle East, and North Africa.
goal statement
The goal of this activity is for learners to be better able to identify patients who may benefit from FcRn blockers in real-world clinical practice and implement them based on the latest clinical data.
learning objectives
accreditation statement
Medscape Education International AG is an EBAC® accredited provider since 2025.